Atara Biotherapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -88.4%
EBITDA: +4.6%
EBIT: +52.9%
EPS: +82.1%
Free cash flow: +61.6%
Operating cash flow: +61.5%

Forward estimates

Revenue: -19.6%
EBITDA: -75.6%
EPS: +140.4%

Three-year CAGR

Revenue: +23.9%
EBITDA: +151.0%
EBIT: +143.0%
Net income: +138.3%
EPS: +122.9%
Free cash flow: +26.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.